Dynamic quotes: Off
|
Company Description (as filed with the SEC)
Lexicon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. We have used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. For targets that we believe have high pharmaceutical value, we engage in programs for the discovery and development of potential new drugs. We have multiple drug programs in various stages of clinical development: • We are developing LX4211, an orally-delivered small molecule compound, as a treatment for type 1 and type 2 diabetes. ... More ...
Analyst Info |
|
| Annual EPS Est: | $-0.23 |
| Quarterly EPS Est: | -0.02 |
| PEG Ratio: | -.01 |
|
Mean Recommendation: View Summary / View All |
1.71 |
Data is provided by Zacks Investment Research

